trastuzumab deruxtecan,ruxolitinib
daiichi sankyo,astrazeneca,incyte,novartis
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 't-dxd', 'destiny,crc,02']
#asco23 t-dxd in patients pts with her2+ mcrc: phase 2 destiny-crc02 study 122 patients previously treated 5.4 vs 6.4 mg orr 37.8% vs 27.5%
mpfs 5.8 vs 5.5 mo
any grade ild 8.4% vs 12.8% (1 pts grade 5) presented by dr. 
Medical Oncologist.                                            
        
On the trail of #SCIENCE to turn cancer into a manageable chronic disease. #bcsm #crcsm